Gamma- glutamylcysteine
Phase 1Small molecule
Gamma- glutamylcysteine is one of 38 small molecule programs targeting Parkinson's Disease. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
50 competitors in Parkinson's Disease
#DrugCompanyPhaseTrials
1Bendopa
MMerz North America, Inc.
Approved
Dayvigo
EisaiApproved
Ingrezza
Neurocrine BiosciencesApproved
Strattera
MMap77
Phase 3
Hytrin
AAbbott
Phase 3
Glucophage
EMD SeronoPhase 3
Micardis
Boehringer IngelheimPhase 3
Ketalar
AAultman Health Foundation
Phase 2
Coreg
Akero TherapeuticsPhase 2
ABBV-951
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gamma- glutamylcysteine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- PPravat Mandal